Summary

Eligibility
for people ages 6-17 (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The purpose of this study is to evaluate the efficacy and safety of guselkumab in pediatric participants aged greater than or equal to 6 through less than 18 years with chronic plaque psoriasis.

Official Title

A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)

Keywords

Psoriasis, Etanercept, Monoclonal Antibodies, Guselkumab

Eligibility

Locations

  • University of California, San Diego
    San Diego California 92123 United States
  • Stanford University
    Palo Alto California 94306 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Janssen Research & Development, LLC
ID
NCT03451851
Phase
Phase 3 Psoriasis Research Study
Study Type
Interventional
Participants
About 120 people participating
Last Updated